Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?

This article was originally published in The Pink Sheet Daily

Executive Summary

At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.

You may also be interested in...

Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments

The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.

Takeda’s Strategic Run Up To Nycomed

With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.

Tudorza’s Delivery System Key To Positioning For COPD Maintenance

Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts